* Respiratory tract infection vaccine immunizes women of
* Co says vaccine induces immune response at levels that can
* Shares up 8.5 pct post market
(Adds analysts' comment, study details)
April 2 Novavax Inc said its vaccine to
treat a virus that causes respiratory tract infections met the
main goal, of immunizing women of childbearing age, in a
The company's shares were up 8.5 percent at $2.35 in
The vaccine against respiratory syncytial virus (RSV) could
induce immune responses at levels that can protect infants
through a transfer of antibodies from the mother, Novavax said
citing trial data.
The vaccine was well-tolerated, with a safety profile
similar to its early-stage trial.
The trial on 330 women tested 60 microgram and 90 microgram
doses of the vaccine, with and without an adjuvant - an agent to
boost immune response. The women received either one or two
injections of a single dose of the vaccine, or a placebo. The
adjuvant showed a greater response in both regimens.
"The study was dose confirmatory at 60 micrograms. They will
go with an adjuvant and will probably go forward testing two
doses administered a month apart, because the greatest response
was with using a two-dose regimen," MLV & Co analyst George
Zavoico told Reuters.
Zavoico said the vaccine was ahead of rivals in development.
Novartis and GenVec Inc are also testing
RSV vaccines in pre-clinical studies.
Novavax would have to do reproductive toxicity tests in
animals before test the vaccine on pregnant women, Zavoico said.
The company is also testing the vaccine in an early-stage
study with elderly patients.
"With the robust response in this trial, I believe that they
will see a response in the elderly as well," Zavoico said.
(Reporting By Vrinda Manocha in Bangalore; Editing by Sreejiraj
Eluvangal and Joyjeet Das)